LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

Search

Kala Pharmaceuticals Inc

Atidarymo kaina

2.52 -3.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.45

Max

2.79

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.6M

-7.6M

Dividendai

By Dow Jones

Kitas uždarbis

2026-08-07

Kala Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-20 23:31; UTC

Karštos akcijos

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026-05-20 22:52; UTC

Pagrindinės rinkos jėgos

Osisko Shares Fall on Planned Convertible Notes Offering

2026-05-20 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-20 23:44; UTC

Uždarbis

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026-05-20 23:35; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026-05-20 23:30; UTC

Rinkos pokalbiai

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026-05-20 23:15; UTC

Rinkos pokalbiai

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026-05-20 23:14; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026-05-20 23:02; UTC

Rinkos pokalbiai

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 22:27; UTC

Rinkos pokalbiai

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026-05-20 22:14; UTC

Rinkos pokalbiai

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026-05-20 22:10; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026-05-20 22:00; UTC

Uždarbis

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026-05-20 21:38; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026-05-20 21:27; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026-05-20 21:20; UTC

Uždarbis

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026-05-20 21:19; UTC

Uždarbis

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026-05-20 21:18; UTC

Uždarbis

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026-05-20 21:17; UTC

Uždarbis

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026-05-20 21:16; UTC

Uždarbis

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Kala Pharmaceuticals Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Ikimokestinis pelnas

Pardavimai

Skolų palūkanų išlaidos

Veiklos pelnas

$

Apie bendrovę Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc
help-icon Live chat